Boston Scientific diskutieren

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Barclays PLC from $78.00 to $86.00. They now have an "overweight" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Citigroup Inc. from $90.00 to $92.00. They now have a "buy" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Raymond James from $91.00 to $94.00. They now have a "strong-buy" rating on the stock.

Hey there! I've been keeping an eye on Boston Scientific lately, and I gotta say, I'm pretty impressed. Their innovative medical devices are really making waves in the industry. Did you know their Eversense CGM system just got FDA approval for a full year of use? That's huge! Plus, their surgical and cardiovascular products are seeing strong demand globally. Sure, there are some headwinds like inflation and supply chain issues, but BSX seems to be navigating them well. With double-digit revenue and earnings growth expected this year, I think there's still room for the stock to run. My target price is $90.50, about 20% upside from here. What do you think - could BSX be a good addition to spice up your portfolio?

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Evercore ISI from $82.00 to $90.00. They now have an "outperform" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Royal Bank of Canada from $85.00 to $95.00. They now have an "outperform" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Truist Financial Co. from $90.00 to $100.00. They now have a "buy" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at BTIG Research from $84.00 to $93.00. They now have a "buy" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Stifel Nicolaus from $85.00 to $100.00. They now have a "buy" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at TD Cowen from $86.00 to $100.00. They now have a "buy" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Bank of America Co. from $90.00 to $100.00. They now have a "buy" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Mizuho from $100.00 to $110.00. They now have an "outperform" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Citigroup Inc. from $92.00 to $98.00. They now have a "buy" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Wells Fargo & Company from $87.00 to $98.00. They now have an "overweight" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Royal Bank of Canada from $95.00 to $98.00. They now have an "outperform" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Morgan Stanley from $92.00 to $100.00. They now have an "overweight" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Sanford C. Bernstein from $92.00 to $100.00. They now have an "outperform" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Wells Fargo & Company from $98.00 to $100.00. They now have an "overweight" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at Citigroup Inc. from $98.00 to $107.00. They now have a "buy" rating on the stock.

Boston Scientific Co. (NYSE: BSX) had its price target raised by analysts at TD Cowen from $100.00 to $110.00. They now have a "buy" rating on the stock.